Anna Gifford - Compass Therapeutics Communications Manager
| CMPX Stock | USD 1.49 0.11 7.97% |
Executive
Anna Gifford is Communications Manager of Compass Therapeutics
| Address | 80 Guest Street, Boston, MA, United States, 02135 |
| Phone | 617 500 8099 |
| Web | https://www.compasstherapeutics.com |
Compass Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2171) % which means that it has lost $0.2171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.32) %, meaning that it created substantial loss on money invested by shareholders. Compass Therapeutics' management efficiency ratios could be used to measure how well Compass Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.35 in 2024. At this time, Compass Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 3.5 M in 2024, whereas Total Assets are likely to drop slightly above 120.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Roman Necina | Hookipa Pharma | 56 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Theresa Lavallee | Coherus BioSciences | 58 | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| MD MBA | SAB Biotherapeutics | 51 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| MRCP MD | Coherus BioSciences | 55 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 |
Compass Therapeutics Leadership Team
Elected by the shareholders, the Compass Therapeutics' board of directors comprises two types of representatives: Compass Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compass. The board's role is to monitor Compass Therapeutics' management team and ensure that shareholders' interests are well served. Compass Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compass Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Kalled, Chief Officer | ||
| Jonathan JD, Head VP | ||
| MD MBA, Chief Officer | ||
| Neil CPA, Vice Finance | ||
| Peter Moesta, Interim CMC | ||
| Anna Gifford, Communications Manager | ||
| Karin BA, VP Operations | ||
| Vered MBA, Pres COO | ||
| Minori MD, Senior Development | ||
| James Kranz, VP Controls |
Compass Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compass Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (65.23) % | ||||
| Current Valuation | 61.35 M | ||||
| Shares Outstanding | 137.59 M | ||||
| Shares Owned By Insiders | 12.04 % | ||||
| Shares Owned By Institutions | 69.19 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 223.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.